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Abstract
Background: Adults with chronic kidney disease (CKD) exhibit alterations in tryptophan metabolism, mainly via
the kynurenine pathway, due to higher enzymatic activity induced mainly by inflammation. Indoles produced by
gut-microflora are another group of tryptophan metabolites related to inflammation and conditions accompanying
CKD. Disruptions in tryptophan metabolism have been associated with various neurological and psychological
disorders. A high proportion of CKD patients self-report symptoms of depression and/or anxiety and decline
in cognitive functioning. This pilot study examines tryptophan metabolism in CKD and explores associations
with psychological and cognitive functioning.
Methods: Twenty-seven adults with CKD were part of 49 patients recruited to participate in a prospective
pilot study, initially with an eGFR of 15–29 mL/min/1.73 m2. Only participants with viable blood samples
and complete psychological/cognitive data at a 2-year follow-up were included in the reported cross-sectional
study. Serum samples were analysed by Liquid Chromatography coupled to Mass Spectrometry, for tryptophan,
ten of its metabolites, the inflammation marker neopterin and the hypothalamic–pituitary–adrenal (HPA) axis
marker cortisol.
Results: The tryptophan breakdown index (kynurenine / tryptophan) correlated with neopterin (Pearson
R = 0.51 P = 0.006) but not with cortisol. Neopterin levels also correlated with indoxyl sulfate (R = 0.68,
P < 0.0001) and 5 metabolites of tryptophan (R range 0.5–0.7, all P ≤ 0.01), which were all negatively related
to eGFR (P < 0.05). Higher levels of kynurenic acid were associated with lower cognitive functioning
(Spearman R = −0.39, P < 0.05), while indole-3 acetic acid (IAA) was correlated with anxiety and depression
(R = 0.52 and P = 0.005, R = 0.39 and P < 0.05, respectively).
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Conclusions: The results of this preliminary study suggest the involvement of inflammation in tryptophan
breakdown via the kynurenine pathway, yet without sparing tryptophan metabolism through the 5-HT (serotonin)
pathway in CKD patients. The multiple moderate associations between indole-3 acetic acid and psychological
measures were a novel finding. The presented pilot data necessitate further exploration of these associations
within a large prospective cohort to assess the broader significance of these findings.
Keywords: Chronic kidney disease, Tryptophan, Kynurenine, Neopterin, Cortisol, Inflammation, Depression,
Anxiety, Cognition
Background
Tryptophan metabolism as well as inflammation and
oxidative stress have been associated with various condi-
tions, including psychiatric disorders [1–6], neurological
diseases [7–9], chronic kidney disease (CKD), the early
onset of cardiovascular disease (CVD) [10–14], and even
kidney allograft rejection [15]. The progression of CKD
to end-stage renal disease (ESRD) is often accompanied
by a decline in health-related quality of life involving
an increase in symptoms of depression, anxiety and a
deterioration in cognitive functioning [16–18]. In CKD
patients these problems are less commonly identified,
investigated and managed, partly due to the overlap
between psychological symptoms and the symptoms of
uraemia. Nevertheless, these symptoms affect the fre-
quency of hospitalisation, adherence with treatment
and play a role in the progression of the disease and
mortality [16, 17, 19]. Early intervention is important,
since inflammation and oxidative stress are already evi-
dent in the moderate stages of CKD [20], and these factors
enhance the metabolism of tryptophan via the kynurenine
pathway. In normal health, the majority of peripheral
tryptophan is degraded in the liver via the kynurenine
pathway by tryptophan 2,3-dioxygenase (TDO), controlled
mainly by tryptophan levels. A further shift towards the
kynurenine pathway occurs in the case of inflammation,
such as in CKD [21] or the chronic low-grade inflam-
mation in elderly people [6]. Pro-inflammatory molecules,
especially the cytokine IFN-γ, activate the enzyme indolea-
mine-(2,3)-dioxygenase (IDO) in extra-hepatic tissues
[22] and also promote the production of neopterin, a
sensitive immune-response marker. When cytokines
activate the hypothalamo-pituitary-adrenal (HPA) axis,
the anti-inflammatory glucocorticoids produced also en-
hance the activity of TDO [1, 7]. Psychological disorders
may be explained by disruptions in tryptophan metabo-
lism in two directions [1]. The first is the high activity of
IDO and TDO, which promote tryptophan breakdown
via the kynurenine pathway, depriving tryptophan hy-
droxylase (TPH) of its substrate in the 5-HT (5-hydroxy
tryptamine, serotonin) pathway, resulting in reduced
serotonin production [5, 23–25]. The second direction is
the neuroactivity of the kynurenine pathway metabolites
(kynurenines) [2, 4, 26, 27], which can originate in
peripheral kynurenine crossing the blood–brain barrier
(BBB), thereby acting independently of brain tryptophan
levels. Oxidative stress and inflammation not only pro-
mote production of kynurenines, but are also induced by
some of the kynurenines (i.e. 3-OH Kynurenine and
quinolinic acid) [1, 2]. Therefore, these metabolites
can contribute non-specifically to different symptoms,
with some kynurenines such as quinolinic acid and
kynurenic acid also possessing specific neuroactivity
[7, 9, 24, 28]. Another type of potentially toxic tryptophan
metabolites are uraemic indoles produced by gut micro-
flora [29–31]. These include indoxyl conjugated to sulfate,
which is associated with ROS formation, CVD and pro-
gression of glomerular sclerosis [13, 32–34]. The symp-
toms of uraemia are affected by the different extent of
metabolite accumulation and varying clearance rates. For
example, uraemic accumulation (compared to normal
blood) can be as high as 60-fold for neopterin, 43-fold for
indoxyl sulfate, and 27-fold for kynurenic acid [35].
As part of a preliminary investigation of serum meta-
bolomics we identified an array of tryptophan meta-
bolites differentiating between haemodialysis patients and
healthy volunteers, as well as between pre- and post-
dialysis samples [36]. These findings, in agreement with
literature values where available [11, 14, 35, 37] led to the
selection of candidate metabolites for the current study.
The study includes the sensitive measurement of serum
metabolites by High-Performance Liquid Chromatography
(HPLC) coupled to Mass Spectrometry (MS).
The present study aims to provide preliminary data
regarding associations between kidney function and
three elements: tryptophan metabolism, markers for
inflammation and oxidative stress, and psychological/
cognitive functioning. Previously published work has
mostly linked pairs of these three elements, as discussed
earlier. Our hypotheses were as follows: (1) neopterin
and/or cortisol are related to tryptophan metabolism and
(2) these markers and/or tryptophan metabolites relate to
the severity of psychological symptoms. The long-term
goal of this research is to improve psychological and cog-
nitive functioning in patients with CKD by minimising
neurotoxic responses. So far, studies have examined the
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effects of psychopharmacological treatments on psy-
chological symptoms (see review [38]), adherence with
haemodialysis treatment and clinical outcomes. In the
complex case of CKD, additional factors should be
taken into account, however there is still insufficient
evidence supported by quantitative studies of relevant
biomarkers and the affected metabolic pathways.
Methods
Participants
The protocol for the Tasmanian Chronic Kidney Disease
study has been published previously [39]. Briefly, clinical
data and serum samples were obtained from 27 patients
who were recruited 2 years earlier (while with CKD
stage 4) via the treating physician, to participate in a
prospective cohort pilot study. The ensuing large-scale
study aims to examine the influence of both biomedical
and psychosocial factors on disease progression, decision
making and length and quality of life in adults residing
in Tasmania, Australia, with severe CKD and prior to
kidney replacement therapy.
Procedure
Participants were sent self-report questionnaires inclu-
ding socio-demographic information, psychological and
cognitive functioning, prior to attending a study clinic
where baseline clinical and laboratory data were collected.
Participants unable to attend a clinic had measurements
taken at their place of residence. Serum samples from
dialysis patients were collected just prior to dialysis
treatment. Samples were stored at −80 °C until analysis
by liquid chromatography-tandem mass spectrometry
(LC-MS/MS). Only participants with viable serum sam-
ples and complete psychological / cognitive data at follow-
up (n = 27) were included in the current study.
Biomedical factors
eGFR was calculated using the CKD-EPI formula from
serum creatinine quantified by enzymatic assay and
IDMS-aligned. Body mass index (BMI) (kg/m2) was
calculated from objectively measured height and weight.
Arterial hypertension was defined as systolic blood pres-
sure ≥140 mmHg, diastolic blood pressure ≥ 90 mmHg,
or patient prescribed antihypertensive medication.
Psychological and cognitive functioning
Depression and anxiety were self-reported using the
Patient Health Questionnaire (PHQ-9) and the Beck
Anxiety Inventory (BAI). The PHQ-9 is a screening
measure for clinical depression and includes nine items.
Respondents self-report how often they experienced each
item during the previous fortnight (between 0, never; to 3,
nearly every day). The threshold for clinical depression in
haemodialysis patients is a score of 10 and above [40],
while levels of 5–9 are generally regarded as mild depres-
sion. The BAI was designed to distinguish between the
symptoms of anxiety and those of depression. It consists
of 21 items, each rated for the bothersomeness of the
symptom in the last month, ranging from 0 (not at all)
to 3 (severely). Out of the maximum score of 63, ≤ 7
is categorized as ’no anxiety‘, 8–15 ’mild anxiety‘, 16–25
’moderate anxiety‘ and over 25 ’severe anxiety’ [41]. Parti-
cipants also completed the cognitive function subscale of
the Kidney Disease Quality of Life short-form (KDQOL-
SF 1.3). The KDQOL-SF combines the 36 generic items of
the SF-36 with 43 kidney disease-targeted items. Eleven
subscales are defined from the kidney disease-targeted
items, resulting in a total of 19 subscales (i.e., eight generic
and 11 targeted to patients with kidney disease and treated
by dialysis). Responses are weighted and transformed
to scores ranging from 0 to 100, with higher scores
indicating better self-assessed health-related quality of life.
Chemicals
Reagents were purchased from Merck (Darmstadt,
Germany) and chemical standards were from Sigma–
Aldrich (WI, USA). A Milli-Q system (Millipore, MA,
USA) was used to purify water for aqueous solutions.
Quantification of serum metabolites
Serum was protein-precipitated with methanol (1:3 v/v),
centrifuged at 16600x g for 15 min at 4 °C (Sigma 1-14 K
Microcentrifuge, Germany), the collected supernatant
dried, and reconstituted in water/acetonitrile (95:5 v/v)
to the original concentration. Quality control (QC) sample
was prepared from a pool of 30 serum samples. Quan-
titation was by calibration plots based on QC spiked
with external calibration standards at a series of seven
concentrations (8000-fold range) spanning physiological
ranges (see Additional file 1: Table S1). Analytes were
separated on a ZORBAX SB-C18 analytical column
(3.5 μm, 3.0x150 mm; Agilent, CA, USA), utilising a
Waters Acquity H-class UPLC system (Waters, MA,
USA) coupled to a Waters Xevo triple quadrupole Mass
Spectrometer (Waters, Manchester, UK). Chromatography
and mass spectrometry conditions are detailed in an
additional file (see Additional file 2). Peak integration
was conducted using Waters MassLynx and Targe-
tLynx software, followed by export to Microsoft Excel
(Microsoft, WA, USA).
Statistical analysis
Correlations between psychological and cognitive mea-
sures, metabolites and patient characteristics were esti-
mated using Spearman rank analysis. Correlations between
metabolites and also between metabolites and patient
characteristics were measured by Pearson’s correlation
test. Comparisons of mean psychological and cognitive
Karu et al. BMC Nephrology  (2016) 17:171 Page 3 of 13
scores between two groups were conducted using Mann–
Whitney U-test. Quantified metabolites were compared
by Student’s t-tests or Welch’s ANOVA with Games-
Howell post-hoc test. Correction for multiple hypotheses
was applied using Benjamini- Hochberg false discovery
rate (FDR). Prior to parametric tests on quantified metab-
olites, data were log-transformed and normal distribution
confirmed by Shapiro-Wilk test. A two-tailed P value <
0.05 was considered statistically significant. Statistical ana-
lysis was conducted using XLStat V. 2014.3.04 (Addinsoft,
Paris, France) and network analysis utilized the software
Vanted V.2.1.0 (IPK, Gatersleben, Germany) [42].
Results
Demographic and clinical data of CKD patients
Clinical and demographic characteristics are detailed in
Table 1. Kidney function at the 2-year follow up exa-
mined in this study, ranged from kidney failure (52 %
at stage 5 CKD: eGFR < 15 mL/min/1.73 m2 or on
haemodialysis) to severe CKD (37 % at stage 4: eGFR
15–29 mL/min/1.73 m2) and a few moderate CKD
(11 % at stage 3b: eGFR > 29 mL/min/1.73 m2).
Tryptophan metabolism and association with clinical
factors
Table 2 summarizes the LC-MS/MS quantified levels
of tryptophan, ten of its metabolites, and also the in-
flammation marker neopterin and the HPA-axis activity
marker cortisol. Uraemic and normal reference levels are
also presented in the table, to support the credibility of
the quantified levels. The variability in uraemic symptoms
observed in the patients is not unexpected, as serum levels
depend on renal function (or dialysis treatment), as well as
on gender, genetic factors, diet and also gut microflora
[37]. This is reflected in the high levels and ranges of
the gut-microflora produced metabolites examined here
(indoxyl sulfate and indole-3 acetic acid, IAA). No corre-
lations were found between the patients’ BMI and any of
the examined metabolites, as shown in Table 3A which
summarizes Pearson correlations between metabolites and
clinical factors. While eGFR and serum creatinine levels
were not related to age, low correlation was observed
between age and tryptophan levels (R = 0.46, P < 0.05).
A negative relation was also found between age and the
tryptophan breakdown index KYN/TRP, which is the rate
of tryptophan conversion to the uraemic molecule kynur-
enine (R = −0.44, P < 0.05). Although age did not show
any correlation with serotonin, it was inversely related to
the serotonin turnover metabolite 5-hydroxy-3-indole
acetic acid (5-OH IAA, R = −0.55, P < 0.01). The quan-
tified metabolites were put into biochemical context via
the schematic overview of tryptophan metabolism illus-
trated in Fig. 1. The flow chart also contains box-plots
depicting the mean serum metabolite levels (in μM)
in patients grouped according to kidney function, to
better represent similarities and trends. Patients re-
ceiving haemodialysis did not have reduced levels of
tryptophan metabolites pre-dialysis compared to non-
dialysed patients with eGFR < 15. The haemodialysis
patients showed higher levels of the uremic molecules
quinolinic acid and kynurenine (Welch’s one-way ANOVA
with Games-Howell post-hoc test, P < 0.01, significant
after FDR correction for multiple hypotheses). In compa-
rison, patients with eGFR ≥ 15 (CKD stages 4 and 3B)
had lower levels of some of the metabolites. The relation
to eGFR and creatinine is further described for the full
cohort by Pearson correlation tests in Table 3. In agreement
Table 1 Demographic and clinical characteristics of Tasmanian
CKD patients participating in the study (n = 27)
Parameter Frequency (%) or
Mean ± SD [Range]
Male (%) 18 (67 %)
Age (years) 76.4 ± 7.3 [60–87]
Education > Year 12 9 (33 %)
Living with a partner 22 (81 %)
Retired 23 (85 %)
Smoker, current or former 16 (59 %)
Body mass index (kg/m2) 29.8 ± 5.1 [21.5–42.4]
Serum creatinine (μmol/L) 336.4 ± 178.2 [121–863]
eGFR (mL/min/1.73 m2) 17.0 ± 8.4 [5–36]
CKD
Stage 3b 3 (11 %)
Stage 4 10 (37 %)
Stage 5 (non-dialysed) 7 (26 %)
Stage 5 (haemodialysis) 7 (26 %)
Depression score (PHQ-9) 3.5 ± 3.5 [0–14]
Anxiety score (BAI) 7.2 ± 6.4 [0–25]
Cognitive functioning (in KDQOL-SF 1.3) 86.2 ± 15.5 [46.7–100]
≥3 comorbidities 14 (52 %)
Diabetes mellitus 7 (26 %)
Hypertension 21 (78 %)
Atherosclerotic heart disease 9 (33 %)
Congestive heart failure 9 (33 %)
Peripheral vascular disease 7 (26 %)
Prescribed antidepressants 3 (11 %)
Prescribed ACE inhibitors 8 (30 %)
Prescribed Angiotensin II Receptor Blockers 8 (30 %)
Prescribed statins 18 (67 %)
Prescribed antibiotics 2 (7 %)
Abbreviations: ACE angiotensin-converting enzyme, BAI, Beck Anxiety Inventory,
CKD chronic kidney disease, eGFR estimated glomerular filtration rate,
KDQOL-SF, Kidney Disease Quality of Life short-form, PHQ-9, Patient
Health Questionnaire
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with previous studies, the tryptophan breakdown index,
KYN/TRP, generally increased with deterioration in kidney
glomerular function (R = −0.64, P < 0.001; Fig. 2a), and
there was a moderate correlation between tryptophan
and kynurenine (R = 0.56, P < 0.01). The two markers
hypothesized to be related to this conversion via TDO
and IDO enzymes were also examined. Cortisol, the HPA
axis activity marker, was within the wide normal range
in all patients and did not show significant associations
with any of the quantified metabolites. On the other
hand, the inflammation marker neopterin significantly
increased as eGFR dropped (R = −0.56, P < 0.01). Although
neopterin was not directly associated with tryptophan
levels, it was significantly correlated with KYN/TRP
(R = 0.55, P < 0.01), and showed moderate positive cor-
relations with six tryptophan metabolites (see Table 3).
These tryptophan metabolites include kynurenine (R =
0.60, P < 0.001; Fig. 2b) and three of its downstream
metabolites, as well as indoxyl sulfate (R = 0.68, P <
0.0001; Fig. 2c). Moreover, moderate positive correla-
tions were persistent between indoxyl sulfate and the
kynurenines above, as well as KYN/TRP (R = 0.69, P <
0.0001). The second bacteria-produced tryptophan me-
tabolite measured here, IAA, is a known uraemic mol-
ecule yet it did not correspond with eGFR or any of the
metabolites, and was highly variable within the groups.
Tryptophan can also be metabolized via the 5-HT
(serotonin) pathway, as depicted in Fig. 1. According to
our results, serum serotonin levels did not differ between
kidney function groups or correlate with eGFR or any of
the metabolites. The serotonin breakdown product 5-OH
IAA, which is not considered a uraemic molecule, was
negatively associated with eGFR (R = −0.67, P < 0.001).
5-OH IAA also highly correlated with KYN/TRP, and
was moderately correlated with neopterin and indoxyl
sulfate (see Table 3).
Association between serum metabolites and
psychological/cognitive functioning
Cognitive functioning was assessed using the cognitive
subscale of the KDQOL-SF 1.3, and the results are sum-
marized in Additional file 3: Table S2A. The cognitive
function subscale has been previously validated in pa-
tients with CKD with a median score of 87 [43]. Here,
the overall median was 93 (n = 27), showing an increase
from the median of 73 in haemodialysis patients (n = 7,
mean = 75), through a median of 93 in non-dialysed pa-
tients with CKD stage 5 (n = 7, mean = 89) to a median
of 100 in the patients with CKD stages 4 and 3b (n = 13,
mean = 91). Of the serum metabolites quantified in this
Table 2 Summary of serum metabolites quantified by LC-MS/MS, with reference values for healthy and uraemic blood
Current study (n = 27) Reference values^
Metabolite Units Mean ± s.d. [range] Healthy adult Uraemic (CKD)
Neopterina nM 81.2 ± 38.2 [42.4–224.6] 5.5 ± 2.0c
8.5 ± 4.4d
329.1 ± 42.7 (max)c
172 ± 88.0e
Cortisol nM 212.9 ± 75.8 [91.4–468.7] 320 ± 190f n/a
Tryptophan μM 27.8 ± 7.9 [10.0–48.5] 54.5 ± 9.7f
31.2 ± 7.4g
62.8 ± 9.3d
17.3 ± 9.7g
28.6 ± 8.8e
Serotonin (5-HT) nM 317.6 ± 221.2 [33.3–825.2] 740 ± 280f,h n/a
5-OH IAA nM 262.6 ± 143.1 [114.2–704.6] 51.6 ± 6.8f n/a
Kynurenineb μM 3.02 ± 0.91 [1.46–5.32] 1.6 ± 0.1f
1.6 ± 0.9g
2.5 ± 0.7d
3.3 ± 0.9i
2.7 ± 1.4g
4.46 ± 2.5e
Kynurenic acidb nM 557.3 ± 336.8 [168.4–1349.0] 30 ± 7c,f
28.6 ± 17.1g
800 ± 400 (max)c,f
336.1 ± 72.6g
Quinolinic acidb μM 1.72 ± 1.07 [0.52–4.97] 0.6 ± 0.3i
0.26 ± 0.1g
9.0 ± 5.4i
7.9 ± 2.8g
Xanthurenic acid nM 417.5 ± 102.8 [207.9–637.2] 21.9 ± 0.98f 170.1 ± 60.0f
Quinaldic acid nM 264.1 ± 164.1 [90.4–671.0] n/a n/a
3-OH Anthranilic acid nM 50.8 ± 16.7 [26.5–95.8] 79 [15.0–209.0]f n/a
Indoxyl sulfateb μM 33.2 ± 33.9 [3.24–133.3] 2.5 ± 1.4c 108.4 ± 61.0c
IAAb μM 4.9 ± 4.0 [1.3–20.9] 2.9 ± 1.7c 11.6 ± 2.2c
Abbreviations: CKD chronic kidney disease, max highest uraemic concentration recorded (presented in case mean uraemic concentration is not available), n/a data
not available, s.d. standard deviation
^Values were converted to molarity where given in g/L
awater-soluble uraemic molecule; bprotein-bound uraemic molecule; cTaken from [35], indicating total values (in case of protein-bound metabolites); dtaken from
[6] for elderly people; ehaemodialysis patients [11]; fHMDB website [71]; gtaken from [14] for plasma from healthy subjects or pre-haemodialysis patients; hdata for
males, for females values are 970 ± 280 nM; i taken from [37]
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Table 3 Pearson correlation matrix of metabolites and clinical data (n = 27)
Neopterin Cortisol Tryptophan Serotonin
(5-HT)
5-OH
IAA
5-OH IAA/5-HT Kynurenine KYN/TRP Kynurenic
acid
Quinolinic
acid
Xanthurenic
acid
Quinaldic
acid
3-OH anthranilic
acid
Indoxyl
sulfate
IAA
A) Clinical
Age −0.17 −0.34 0.46* −0.03 −0.55** −0.26 −0.37 −0.44* 0.02 −0.15 0.19 −0.23 −0.22 −0.24 0.17
BMI −0.23 0.32 −0.27 −0.10 −0.05 0.06 −0.25 0.03 0.06 0.14 −0.21 −0.26 −0.19 −0.18 −0.30
Serum
creatinine
0.65*** −0.15 −0.10 0.04 0.66*** 0.31 0.53** 0.71*** 0.17 0.43* 0.12 0.71*** 0.63*** 0.78*** 0.04
eGFR −0.56** 0.07 0.16 0.001 −0.67*** −0.35 −0.46* −0.64*** −0.11 −0.41* −0.01 −0.63*** −0.51** −0.71*** 0.12
B) Metabolites
Neopterin 1
Cortisol −0.13 1
Tryptophan 0.12 −0.29 1
Serotonin
(5-HT)
0.11 −0.06 −0.05 1
5-OH IAA 0.50** 0.05 −0.37 −0.02 1
5-OH IAA/5-HT 0.17 0.08 −0.15 −0.86*** 0.53** 1
Kynurenine 0.60*** −0.28 0.56** −0.03 0.39* 0.21 1
KYN/TRP 0.55** −0.04 −0.45* 0.03 0.83*** 0.40* 0.46* 1
Kynurenic acid 0.26 0.06 0.11 −0.16 0.07 0.18 0.32 0.17 1
Quinolinic acid 0.52** −0.01 0.05 −0.04 0.33 0.20 0.49** 0.44* 0.05 1
Xanthurenic
acid
0.21 −0.09 0.56** 0.005 −0.18 −0.10 0.37 −0.20 −0.05 0.39* 1
Quinaldic acid 0.67*** 0.05 0.05 0.10 0.64*** 0.25 0.60*** 0.61*** 0.37 0.23 0.10 1
3-OH Anth
acid
0.71*** 0.003 0.13 0.11 0.35 0.09 0.57** 0.46* 0.48* 0.49** 0.30 0.75*** 1
Indoxyl sulfate 0.68*** −0.15 −0.23 0.09 0.58** 0.22 0.44* 0.69*** 0.22 0.50** −0.06 0.71*** 0.63*** 1
IAA 0.07 0.10 0.17 −0.20 0.01 0.17 0.24 0.07 0.14 0.05 0.22 0.09 0.20 −0.07 1
Abbreviations: 5-HT serotonin, Anth anthranilic, BMI body mass index, eGFR estimated glomerular filtration rate, IAA indole-3-acetic acid, KYN kynurenine, TRP tryptophan
Significance levels: *P < 0.05; **P < 0.01; ***P < 0.001
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study, high levels of kynurenic acid were associated with
low cognitive functioning (R = −0.39, P < 0.05).
Depressive symptoms at a mild-moderate level were
endorsed by 9 patients (33 %), while 2 patients met the
threshold for clinical depression. Additional file 3: Table
S2B reports the proportion of patients endorsing each
depressive symptom (yes/no), with fatigue (66 %), sleep
problem (44 %) and poor appetite (26 %) being the most
prevalent. Of note, anhedonia (loss of interest in previ-
ously rewarding or enjoyable activities) which is one of
the core symptoms of clinical depression was endorsed
by 26 % of patients. The clinical parameters were not as-
sociated with any depressive symptoms. Of the quanti-
fied metabolites, IAA was the only metabolite to show
significant correlation with the PHQ9 overall score
(R = 0.39, P < 0.05), owing to low-moderate associations
with the subscales sleep (R = 0.49, P < 0.01) and depression
mood (R = 0.50, P < 0.01) which also correlated with
3-OH anthranilic acid (R = 0.40, P < 0.05). The asso-
ciation between the serotonin turnover (5-OH IAA/5-HT)
and the symptom of poor appetite was the strongest
recorded of any PHQ9 subscale (R = 0.51, P < 0.01). Inter-
estingly, within the group of patients with ESRD (CKD
stage 5, n = 14), serotonin and 5-OH IAA/5-HT showed
moderate association with the total PHQ9 (R = −0.55,
R = 0.59, respectively. both P < 0.05), and with the anhe-
donia subscale (R = −0.59, R = 0.69, respectively. both
P < 0.05).
Additional file 3: Table S2C displays the prevalence of
anxiety as measured by the 21 subscales of the BAI test.
(See figure on previous page.)
Fig. 1 A schematic diagram of Tryptophan metabolism, including box plots of quantified metabolites. Metabolites are in squares, enzymes
in circles (yellow affected by cytokines, pink by cortisol), double-tip arrow indicates multi-step metabolism, Green arrow and metabolite
are produced only by gut microflora. Box plots depict mean levels ± s.d (μM) grouped by kidney function, from left to right: blue, 15 ≤
eGFR ≤ 36 (CKD stage 3b-4, n = 13); red, eGFR < 15 (CKD stage 5, non-dialysis); grey, Haemodialysis patients (CKD stage 5). For each metabolite,
a horizontal line under a pair of box plots indicates a non-significant difference in mean values (Welsh’s one-way ANOVA with Games-Howell
post-hoc test, P > 0.05). Abbreviations: ACSAD, 2-amino-3-carboxymuconate semialdehyde; ALDH, aldehyde dehydrogenase; Anth A, anthranilic
acid; CKD, chronic kidney disease; DDC, aromatic amino acid decarboxylase; eGFR, estimated glomerular filtration rate; IAA, indole-3-acetic
acid; IDO, indoleamine-(2,3)-dioxygenase; IFNγ, interferon-γ; KAT, kynurenine aminotransferase; KMO, kynurenine 3-monooxygenase; KYN,
kynurenine; KYNA, kynurenic acid; KYNU, Kynureninase ; MAO, monoamine oxidase ; NAD+, Nicotinamide adenine dinucleotide; N-F, N-formyl;
PicoA, picolinic acid; QuinaA, quinaldic acid; QuinoA, quinolinic acid; SULT, sulfotransferase; TDO, tryptophan 2,3-dioxygenase; TPH, tryptophan
hydroxylase; UGT, UDP glucuronosyltransferase; XanthA, xanthurenic acid
a b
c
Fig. 2 Scatter plots depicting relationships between serum metabolites. a tryptophan breakdown index (KYN/TRP) vs. eGFR; b kynurenine
vs. neopterin; c neopterin vs. indoxyl sulfate. Marker colours indicate kidney function, and not used for separate calculations: red, CKD
stage 5 (empty, HD; full, non-HD); blue, CKD stage ≤ 4. Pearson correlation tests (n = 27) were conducted on log-transformed data as
required, then back-transformed for presentation in this figure. Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular
filtration rate; HD, haemodialysis; KYN, kynurenine; TRP, tryptophan
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Twenty patients (74 %) reported at least three symptoms
of anxiety, with two patients being classified as experien-
cing “moderate anxiety” and seven patients experiencing
“mild anxiety”. Similarly to depressive symptoms, IAA
displayed the strongest associations with anxiety symp-
toms (5 subscales) and the only moderate significant
correlation with the total score (R = 0.52; P < 0.01). Six
additional quantified metabolites showed significant yet
low-to-moderate associations with anxiety subscales
which were reported by at least 30 % of patients. eGFR
showed low negative association with the subscale of
indigestion, while three metabolites were moderately
correlated with this subscale. Again, within the group
of patients with ESRD (n = 14) multiple associations were
found between subscales of anxiety, and serotonin and
its turnover. The correlations between 5-OH IAA/5-HT
and eight anxiety subscales led to a stronger positive
correlation with total BAI score (R = 0.70, P = 0.005).
Of note, seven of these subscales were complementary
to those correlated with IAA.
Differences based on prescribed medication
Some pharmaceuticals, especially antibiotics, ACE in-
hibitors and statins, affect inflammation and oxidative
stress. Therefore, the corresponding levels of metabo-
lites and scores were also compared between patients
based on prescribed medication. The group of eight
patients prescribed ACE inhibitors showed marginally
lower levels of quinolinic acid and 3-OH anthranilic
acid (all t-test P < 0.05). This group had a slightly higher
depression score (total PHQ9 mean of 5.6 vs. 2.6; Mann–
Whitney P = 0.013) and a higher anxiety score (total BAI
mean of 11.2 vs. 5.4; P = 0.018). For ARB (Angiotensin II
Receptor Blockers) and statins, no significant associations
with metabolite levels were observed. The group that
was prescribed statins (n = 18) displayed significantly
lower anxiety (total BAI score mean of 4.5 vs. 12.4; P =
0.003) and also better cognitive functioning (mean of
91 vs. 76; P = 0.02). Only two patients were prescribed an-
tibiotics, hence no statistical investigation was followed.
Although less reliable to interpret due to the limita-
tions of size and multiple unbalanced factors, medication
should be taken into account when planning a larger
cohort study.
Discussion
This pilot study brings together data from different
research areas, exploring associations between CKD
progression, tryptophan metabolites, markers for inflam-
mation and HPA activity, and psychological/cognitive
functioning. There are a number of limitations of the
current analysis that should be acknowledged. As this
study was originally designed as a pilot to assess the feasi-
bility of a larger cohort study, a formal power calculation
was not performed. Another substantial limitation of the
study design is the lack of healthy controls, dictated by the
design of the Tasmanian CKD pilot study, as described in
published work [39]. Results should therefore be treated
as preliminary and interpreted with caution. In addition,
due to the cross-sectional analysis, the direction of causa-
lity cannot be inferred. Further, it should be noted that
depressive and anxiety symptoms, and cognitive functio-
ning were assessed via self-report rather than standardized
clinical interviews. While this approach may underes-
timate the prevalence of these disorders, all the self-report
measures used in the current study have been validated in
renal populations and are brief and easy to administer and
interpret.
Our findings of increased tryptophan catabolites with
deteriorating kidney function were mostly expected ac-
cording to the literature, where available (Table 2). As
we hypothesized, the high levels of the inflammation
marker neopterin correlated with the tryptophan to kynure-
nine breakdown index. Similar correlations between KYN/
TRP and neopterin were previously shown in haemodialysis
patients [11] and in cases of kidney allograft rejection [15].
This was attributed to IDO-induced activation through
inflammation [1, 2, 5, 7], and is in agreement with a CKD
study by Schefold et al. who correlated other inflammatory
markers with KYN/TRP [21]. Neopterin correlations
found in the current study also included metabolites
downstream in the kynurenine pathway: Quinolinic acid
(as seen in [21]), 3-OH anthranilic acid, and also quinaldic
acid, the redox product of kynurenic acid (showed correl-
ation in [21]). Cortisol exhibited only non-significant
trend towards negative associations with tryptophan and
kynurenine, thus in this cohort we do not support the
hypothesis concerning its involvement in tryptophan
metabolism to kynurenine via TDO activation. This obser-
vation may, however, reflect inconsistent cortisol levels in
the small cohort due to medications (i.e. ACE inhibitors),
circadian variations and possible glucocorticoids resis-
tance in some patients [44]. IDO activity may be indirectly
induced by indoxyl sulfate [31], which promotes inflam-
mation and oxidative stress [33]. The positive correlation
we found between neopterin and indoxyl sulfate (R = 0.68;
P < 0.0001) along with correlations between indoxyl sulfate
and four kynurenines may further strengthen its link to
inflammation and kynurenines production. This aspect
also warrants further investigation in larger studies. With
regard to the negative association we reported between
indoxyl sulfate and eGFR (R = −0.71; P < 0.0001), it is
debatable whether to expect a relationship with eGFR,
since its clearance may be ruled by tubular secretion
[45–47] or by glomerular filtration [48]. Regardless of the
clearance mechanism, its inverse relationship to eGFR
was demonstrated in several studies and was related to
acceleration in the progression of CKD [34]. The increased
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tryptophan degradation via the kynurenine pathway, as
observed in CKD, was proposed to be responsible for
disruptions in the 5-HT pathway due to the loss of
the precursor tryptophan [5, 23–25]. Criticisms of this
hypothesis include the observation that in depressed
patients, despite the inflammatory phenotype, the deple-
tion of tryptophan was without changes in kynurenine
pathway metabolites, expression of IDO or even the sero-
tonin transporter (SERT) [49]. In our preliminary study
with the low number of mostly mild depressive symptoms
expressed by participants, the induced tryptophan meta-
bolism via the kynurenine pathway did not seem to hinder
metabolism via the 5-HT pathway. It is unclear whether
the elevated levels of 5-OH IAA can be attributed to
higher serotonin turnover or to uremic accumulation of
5-OH IAA. Nevertheless, a 9-fold increase of 5-OH IAA
in CKD patients compared to healthy controls has been
recorded before [50], and with our observation of asso-
ciation with eGFR, it may support the use of 5-OH IAA as
a uraemic marker in CKD.
The second hypothesis in our work suggested asso-
ciation between metabolites (mainly kynurenines) and
psychological/cognitive measures, possibly due to their
neuroactivity. Our results revealed only a few associa-
tions between metabolites and psychological scores and
subscales. As suggested in a recent review by Lopresti et
al. [51], this lack of associations can result from diffe-
rences between studies (type and level of psychological
symptoms; comorbidities; treatment; study design; sample
size). It can also originate in the involvement of additional
biochemical mechanisms, not examined here, which are
of high impact in CKD patients. The frequency of cogni-
tive impairment estimated in the current study followed
the expected pattern matching kidney function and treat-
ment [52]. A low yet significant negative association
was found between kynurenic acid and cognitive function,
similarly to other studies [7, 24, 53], which regarded
kynurenic acid as neurotoxic rather than neuroprotective
(as previously hypothesized [28]). Also, we found no asso-
ciations with the ratio kynurenic acid/kynurenine, termed
the “neuroprotective ratio” in depression studies [28]. The
neurotoxicity of kynurenic acid was partly explained by
the effects of kynurenines on the nicotinic cholinergic
system [54]. Kynurenic acid is a NMDA (N-Methyl-D-
aspartate) receptor antagonist [5, 9, 28], unlike quinolinic
acid, a NMDA receptor agonist which causes excitotoxic
neurodegenerative changes [4, 7]. However, kynurenic
acid has higher affinity to α-7-nicotinic acetylcholine
receptors [4, 24, 54] and this can change its activity from
neuroprotective to neurotoxic. The haemodialysis clea-
rance of kynurenic acid, along with other kynurenines, is
still insufficient despite advances in dialysis [12, 14, 21, 36].
The development of cognition-enhancement medica-
tion is an ongoing effort to address brain diseases, and
these include pharmaceuticals that reduce the formation
of kynurenic acid in the brain. Different approaches have
been taken, for example by specific targeting of kynure-
nine aminotransferase II (KAT II, see Fig. 1) [55], which
showed improved cognitive behaviour in mice lacking
the expression of the enzyme [56]. Currently there is no
standard treatment to eliminate kynurenines, and this
emphasizes the need to reduce kynurenines formation via
control of inflammation and other factors which contrib-
ute to tryptophan catabolism into kynurenines, including
reduced consumption of tryptophan. An example for
one approach is the treatment with selective vitamin
D receptor activators (such as paricalcitol), which reduced
inflammation and oxidative stress in renal patients under-
going haemodialysis [57]. Contrary to our hypothesis,
mainly non-kynurenines were associated with depression
and anxiety scales in our study. The self-reported com-
plaints were mainly of low or mild symptoms, thus
differing from other studies investigating tryptophan
metabolism, especially in the field of psychiatry and brain
diseases. Tryptophan itself did not correlate with any of
the subscales, agreeing with a similar observation for a
single subscale reflecting fatigue (SF-36 vitality) in haemo-
dialysis patients [58]. 5-OH IAA along with serotonin
turnover (5-OH IAA / 5-HT), were suggested before to
serve as markers for evaluation of depression [59, 60]. The
two markers were associated with a few subscales of
depression and anxiety in our study. The multiple asso-
ciations with subscales and also with total anxiety and
depression scores found in patients with ESRD are of low
statistical power. Nevertheless, the 5-HT pathway should
not be neglected in future CKD studies in this context,
also following evidence that serotonin is decreased in
haemodialysis [21, 36], and data supporting the role of
melatonin in fatigue symptoms of people with CKD [25].
Current guidelines recommend the use of an SSRI (selec-
tive serotonin reuptake inhibitor) as a first-line agent
where treatment with antidepressants is considered in
CKD patients [38]. Still, there is a lack of well-controlled
trials that support or refute the efficacy and safety of anti-
depressant medications in patients with CKD [38, 61, 62].
This gap in medical evidence contributes to the status of
clinical depression as under-recognized and an under-
treated problem in this patient population. The trypto-
phan metabolites involving gut microflora gained our
attention due to some surprising findings. Despite very
high serum levels and extensive inter-metabolite correla-
tions, indoxyl sulfate was only associated with one sub-
scale of anxiety and not with any depressive symptoms.
This, unfortunately, prevents a comparison with the intri-
guing report of lower serum indoxyl sulfate in depressed
haemodialysis patients (compared to non-depressed pa-
tients) [63]. A novel finding in this pilot study is the role
of indole-3-acetic acid (IAA) as the major metabolite
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related to both anxiety and depressive symptoms in CKD
patients. IAA is a known uraemic molecule, and although
its levels were not associated with serum creatinine or
eGFR, they were elevated in some patients. IAA can be
generated in the intestines from indole produced by gut
microflora [30], or metabolized in tissue from tryptamine
[64] and other tryptophan derivatives. IAA at uremic con-
centrations was previously linked to oxidative stress and
contribution to development of CVD in CKD patients via
activation of the Aryl Hydrocarbon Receptor [13]. The only
literature we found relating IAA to psychiatry research in-
cluded early studies in severely depressed patients, showing
no change in urinary excretion of IAA throughout the
stages of disease and recovery, despite a drop in tryptamine
excretion [65] or plasma tryptophan [64]. In our work, the
minimal relation between IAA and all other measured me-
tabolites suggests the involvement of additional metabolic
transformations not examined here, or subject-specific dif-
ferences in its production and catabolism which obscured
significant findings. Haemodialysis is rather limited in
improving the clearance of indole-based uraemic toxins
produced by gut microflora [33], depending on their con-
jugates and affinity to albumin. The intestinal absorption
of indoles may be reduced by the orally-administered
carbon-adsorbent AST-120. Adding this pharmaceutical
to the standard therapy of CKD patients showed reduced
serum levels of indoxyl sulfate [32, 66], improvement in
some of the uraemia symptoms [66] and a decrease in
markers for cardiovascular disease [67]. Although clinical
trials showed that treatment with AST-120 resulted in
more gradual disease progression [66, 68], its overall
benefit is yet to be proven [68, 69]. Other approaches
to reducing gut-microflora-produced uraemic molecules
are consumption of a low-protein diet and restoring the
balance of gut microflora by probiotics and prebiotics
[30, 34, 70]. It would be interesting to examine the effects
of such approaches on patients in various stages of CKD
(including transplant and haemodialysis patients), and
measure uraemic indole derivatives, tryptophan metabo-
lites, inflammation markers and psychological variables.
Conclusions
Our observations suggest that a decline in kidney func-
tion is associated with an increase in the inflammation
marker neopterin and metabolism of tryptophan via
the kynurenine pathway, without evident elimination
of tryptophan metabolism via the 5-HT pathway. We
also found along the continuum of CKD significant
associations between neopterin, indoxyl sulfate, kynure-
nine and its downstream metabolites, as well as several
associations with cognitive function and subscales of
depression and anxiety. Of the quantified metabolites, the
non-kynurenine IAA displayed consistent associations
with symptoms of anxiety and depression, reported mostly
at low to mild levels in the study. These pilot data suggest
that further more detailed investigation of these asso-
ciations is warranted. Exploration within a larger prospect-
ive cohort may provide a novel direction in improving
psychological and cognitive well-being in this patient
population.
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